{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:01:23Z","timestamp":1740124883604,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,8,24]]},"DOI":"10.1038\/s41416-024-02752-1","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T15:02:25Z","timestamp":1718636545000},"page":"589-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications"],"prefix":"10.1038","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7274-9622","authenticated-orcid":false,"given":"Sutapa","family":"Sinha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles D.","family":"Del Busso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Boysen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda E.","family":"Wellik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4885-094X","authenticated-orcid":false,"given":"Asish K.","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"2752_CR1","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1093\/jnci\/84.18.1422","volume":"84","author":"LB Travis","year":"1992","unstructured":"Travis LB, Curtis RE, Hankey BF, Fraumeni JF Jr. Second cancers in patients with chronic lymphocytic leukemia. J Natl Cancer Inst. 1992;84:1422\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"2752_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","volume":"30","author":"JD Brewer","year":"2012","unstructured":"Brewer JD, Shanafelt TD, Otley CC, Roenigk RK, Cerhan JR, Kay NE, et al. Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study. J Clin Oncol. 2012;30:843\u20139.","journal-title":"J Clin Oncol."},{"key":"2752_CR3","first-page":"571","volume":"10","author":"O Onajin","year":"2012","unstructured":"Onajin O, Brewer JD. Skin cancer in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2012;10:571\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"key":"2752_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JOP.2013.000921","volume":"10","author":"AS Mansfield","year":"2014","unstructured":"Mansfield AS, Rabe KG, Slager SL, Schwager SM, Call TG, Brewer JD, et al. Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. J Oncol Pr. 2014;10:e1\u20134.","journal-title":"J Oncol Pr"},{"key":"2752_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1001\/jamadermatol.2013.6249","volume":"150","author":"NF Velez","year":"2014","unstructured":"Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014;150:280\u20137.","journal-title":"JAMA Dermatol"},{"key":"2752_CR6","doi-asserted-by":"publisher","first-page":"8818","DOI":"10.18632\/oncotarget.2422","volume":"5","author":"H Axelrod","year":"2014","unstructured":"Axelrod H, Pienta KJ. AXL as a mediator of cellular growth and survival. Oncotarget. 2014;5:8818\u201352.","journal-title":"Oncotarget"},{"key":"2752_CR7","doi-asserted-by":"publisher","first-page":"20210928.","DOI":"10.3390\/cancers13194864","volume":"13","author":"A Auyez","year":"2021","unstructured":"Auyez A, Sayan AE, Kriajevska M, Tulchinsky E. AXL receptor in cancer metastasis and drug resistance: when normal functions go askew. Cancers. 2021;13:20210928.","journal-title":"Cancers"},{"key":"2752_CR8","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood-2010-09-305649","volume":"117","author":"AK Ghosh","year":"2011","unstructured":"Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D, et al. The novel receptor tyrosine kinase AXL is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. Blood. 2011;117:1928\u201337.","journal-title":"Blood"},{"key":"2752_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","volume":"122","author":"I Ben-Batalla","year":"2013","unstructured":"Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, et al. AXL, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood. 2013;122:2443\u201352.","journal-title":"Blood"},{"key":"2752_CR10","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/sj.bjc.6603135","volume":"94","author":"J Green","year":"2006","unstructured":"Green J, Ikram M, Vyas J, Patel N, Proby CM, Ghali L, et al. Overexpression of the AXL tyrosine kinase receptor in cutaneous SCC-derived cell lines and tumours. Br J Cancer. 2006;94:1446\u201351.","journal-title":"Br J Cancer"},{"key":"2752_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/jmcb\/mjw045","volume":"9","author":"A de Polo","year":"2017","unstructured":"de Polo A, Luo Z, Gerarduzzi C, Chen X, Little JB, Yuan ZM. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex. J Mol Cell Biol. 2017;9:154\u201365.","journal-title":"J Mol Cell Biol"},{"key":"2752_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nm.4472","volume":"24","author":"J Boshuizen","year":"2018","unstructured":"Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, et al. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF\/MEK inhibitors. Nat Med. 2018;24:203\u201312.","journal-title":"Nat Med"},{"key":"2752_CR13","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1182\/blood-2009-09-242719","volume":"115","author":"AK Ghosh","year":"2010","unstructured":"Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010;115:1755\u201364.","journal-title":"Blood"},{"key":"2752_CR14","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-14-1892","volume":"21","author":"S Sinha","year":"2015","unstructured":"Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, et al. Targeted AXL inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic\/additive effects in combination with BTK inhibitors. Clin Cancer Res. 2015;21:2115\u201326.","journal-title":"Clin Cancer Res"},{"key":"2752_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1136\/jcp.50.10.801","volume":"50","author":"PJ van Diest","year":"1997","unstructured":"van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J, et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. J Clin Pathol. 1997;50:801\u20134.","journal-title":"J Clin Pathol"},{"key":"2752_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1021\/ml200198x","volume":"2","author":"A Mollard","year":"2011","unstructured":"Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, et al. Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors. ACS Med Chem Lett. 2011;2:907\u201312. https:\/\/doi.org\/10.1021\/ml200198x","journal-title":"ACS Med Chem Lett"},{"key":"2752_CR17","doi-asserted-by":"publisher","first-page":"12885","DOI":"10.1073\/pnas.0806202105","volume":"105","author":"F Pichiorri","year":"2008","unstructured":"Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA. 2008;105:12885\u201390.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2752_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13293-015-0021-2","volume":"6","author":"M Jayachandran","year":"2015","unstructured":"Jayachandran M, Lugo G, Heiling H, Miller VM, Rule AD, Lieske JC. Extracellular vesicles in urine of women with but not without kidney stones manifest patterns similar to men: a case control study. Biol Sex Differ. 2015;6:2.","journal-title":"Biol Sex Differ"},{"key":"2752_CR19","doi-asserted-by":"publisher","first-page":"H931","DOI":"10.1152\/ajpheart.00193.2008","volume":"295","author":"M Jayachandran","year":"2008","unstructured":"Jayachandran M, Litwiller RD, Owen WG, Heit JA, Behrenbeck T, Mulvagh SL, et al. Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol. 2008;295:H931.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2752_CR20","doi-asserted-by":"publisher","first-page":"15705","DOI":"10.1074\/jbc.M116.771485","volume":"292","author":"KS Gajiwala","year":"2017","unstructured":"Gajiwala KS, Grodsky N, Bolanos B, Feng J, Ferre R, Timofeevski S, et al. The AXL kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase. J Biol Chem. 2017;292:15705\u201316.","journal-title":"J Biol Chem"},{"key":"2752_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ebiom.2018.09.006","volume":"36","author":"YY Li","year":"2018","unstructured":"Li YY, Tao YW, Gao S, Li P, Zheng JM, Zhang SE, et al. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p. EBioMedicine. 2018;36:209\u201320.","journal-title":"EBioMedicine"},{"key":"2752_CR22","doi-asserted-by":"publisher","first-page":"37173","DOI":"10.18632\/oncotarget.26444","volume":"9","author":"S Sinha","year":"2018","unstructured":"Sinha S, Boysen JC, Chaffee KG, Kabat BF, Slager SL, Parikh SA, et al. Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. Oncotarget. 2018;9:37173\u201384.","journal-title":"Oncotarget"},{"key":"2752_CR23","first-page":"20200402.","volume":"9","author":"H Kim","year":"2020","unstructured":"Kim H, Lee S, Shin E, Seong KM, Jin YW, Youn H, et al. The emerging roles of exosomes as EMT regulators in cancer. Cells. 2020;9:20200402.","journal-title":"Cells"},{"key":"2752_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1038\/onc.2013.57","volume":"33","author":"MK Asiedu","year":"2014","unstructured":"Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014;33:1316\u201324.","journal-title":"Oncogene"},{"key":"2752_CR25","first-page":"1900","volume":"15","author":"G Zhang","year":"2018","unstructured":"Zhang G, Kong X, Wang M, Zhao H, Han S, Hu R. et al. AXL is a marker for epithelial-mesenchymal transition in esophageal squamous cell carcinoma. Oncol Lett. 2018;15:1900\u20136.","journal-title":"Oncol Lett"},{"key":"2752_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1073\/pnas.0909333107","volume":"107","author":"C Gjerdrum","year":"2010","unstructured":"Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, et al. AXL is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA. 2010;107:1124\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2752_CR27","doi-asserted-by":"publisher","first-page":"100773.","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13:100773.","journal-title":"Transl Oncol"},{"key":"2752_CR28","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1242\/dev.139071","volume":"143","author":"K Campbell","year":"2016","unstructured":"Campbell K, Casanova J. A common framework for EMT and collective cell migration. Development. 2016;143:4291\u20134300.","journal-title":"Development"},{"key":"2752_CR29","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/bjc.1996.642","volume":"74","author":"F Levi","year":"1996","unstructured":"Levi F, Randimbison L, Te VC, La Vecchia C. Non-Hodgkin\u2019s lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer. 1996;74:1847\u201350.","journal-title":"Br J Cancer"},{"key":"2752_CR30","first-page":"337","volume":"61","author":"MH Greene","year":"1978","unstructured":"Greene MH, Hoover RN, Fraumeni JF Jr. Subsequent cancer in patients with chronic lymphocytic leukemia-a possible immunologic mechanism. J Natl Cancer Inst. 1978;61:337\u201340.","journal-title":"J Natl Cancer Inst"},{"key":"2752_CR31","doi-asserted-by":"crossref","unstructured":"Ishdorj G, Beiggi S, Nugent Z, Streu E, Banerji V, Dhaliwal D, et al. Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival. Leuk Lymphoma 2019;60:3204\u201313.","DOI":"10.1080\/10428194.2019.1620941"},{"key":"2752_CR32","first-page":"4772","volume":"128","author":"G Kleinstern","year":"2016","unstructured":"Kleinstern G, Rishi A, Achenbach SJ, Chaffee KR, Kay NE, Shanafelt TD, et al. Skin cancers among chronic lymphocytic leukemia (CLL) patients - the effect of uv radiation and cll clinical characteristics. Blood-ASH Abstr. 2016;128:4772.","journal-title":"Blood-ASH Abstr"},{"key":"2752_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1090-3","volume":"18","author":"C Zhu","year":"2019","unstructured":"Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18:153.","journal-title":"Mol Cancer"},{"key":"2752_CR34","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-14-2648","volume":"21","author":"TM Brand","year":"2015","unstructured":"Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, et al. AXL Is a logical molecular target in head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21:2601\u201312.","journal-title":"Clin Cancer Res"},{"key":"2752_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09078-z","volume":"12","author":"M Nyakas","year":"2022","unstructured":"Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, et al. AXL inhibition improves BRAF-targeted treatment in melanoma. Sci Rep. 2022;12:5076.","journal-title":"Sci Rep"},{"key":"2752_CR36","doi-asserted-by":"publisher","first-page":"e0227187.","DOI":"10.1371\/journal.pone.0227187","volume":"15","author":"K Flem-Karlsen","year":"2020","unstructured":"Flem-Karlsen K, Nyakas M, Farstad IN, McFadden E, Wernhoff P, Jacobsen KD. et al. Soluble AXL as a marker of disease progression and survival in melanoma. PloS one. 2020;15:e0227187.","journal-title":"PloS one"},{"key":"2752_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/jid.2010.326","volume":"131","author":"ES Papadakis","year":"2011","unstructured":"Papadakis ES, Cichon MA, Vyas JJ, Patel N, Ghali L, Cerio R, et al. Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members. J Invest Dermatol. 2011;131:509\u201317.","journal-title":"J Invest Dermatol"},{"key":"2752_CR38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.26502\/jcsct.5079091","volume":"4","author":"SM Landers","year":"2020","unstructured":"Landers SM, Bhalla AD, Ma X, Lusby K, Ingram D, Al Sannaa G, et al. AXL Inhibition enhances MEK inhibitor sensitivity in malignant peripheral nerve sheath tumors. J Cancer Sci Clin Ther. 2020;4:511\u201325.","journal-title":"J Cancer Sci Clin Ther"},{"key":"2752_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00426-2","volume":"11","author":"S Sinha","year":"2021","unstructured":"Sinha S, Secreto CR, Boysen JC, Lesnick C, Wang Z, Ding W, et al. Upregulation of AXL and beta-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance. Blood Cancer J. 2021;11:37.","journal-title":"Blood Cancer J"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02752-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02752-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T15:09:21Z","timestamp":1722870561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02752-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,8,24]]}},"alternative-id":["2752"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02752-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2024,6,17]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS, RG, MDB, WH, JB, LEW, AKG-No conflicts. NEK-Advisory Board for: AbbVie, Astra Zeneca, Beigene, Behring, Boehringer Ingelheim Pharmaceuticals, Inc., Dava Oncology, Janssen, Juno Therapeutics, Pharmacyclics. DSMC (Data Safety Monitoring Committee) for: Agios Pharm, Astra Zeneca, BMS \u2013Celgene, Dren Bio Janssen, Research funding from: AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, Pharmacyclics, Sunesis, Vincerx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All healthy individuals and CLL patients provided written informed consent according to the Declaration of Helsinki to the Mayo Clinic Institutional Review Board, which approved these studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}